oncology home hero banner oncology home mobile hero banner
  • PRODUCT NAME
  • DISEASE AREA

Filter by

  • CONTENT TYPE

Would you like to submit a medical inquiry?

Would you like to connect with an MSL?

Search result(s) may include information that is not consistent with the product’s Full Prescribing Information. Eisai does not recommend uses that are inconsistent with the Full Prescribing Information.

Please note that HALAVEN is approved for those indications and dosages that appear in the HALAVEN Full Prescribing Information. The information provided below and/or its appendices may summarize publications or guidelines that describe indications or treatment modalities for the use of HALAVEN that have not been approved by the Food and Drug Administration.

The information below is provided by Eisai Inc. and is intended to assist you in forming your own clinical conclusions regarding the use of Eisai products. Eisai Inc. does not recommend or endorse the use of this product in any manner other than as described in the Full Prescribing Information.

Adverse reactions, some of which can be serious or fatal, may occur with HALAVEN including neutropenia, peripheral neuropathy, embryo-fetal toxicity, and QT Prolongation. Click here for Important Safety Information.

HALAVEN is a microtubule inhibitor indicated for the treatment of patients with:

  • For the treatment of patients with metastatic breast cancer (mBC) who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.
  • For the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen

Prescribing Information for HALAVEN® (eribulin mesylate) VIEW/DOWNLOAD

Please note that LENVIMA is approved only for those indications and dosages that appear in the LENVIMA Full Prescribing Information. The information provided below and/or its appendices may summarize publications or guidelines that describe indications or treatment modalities for the use of LENVIMA that have not been approved by the Food and Drug Administration.

The information below is provided by Eisai Inc. and is intended to assist you in forming your own clinical conclusions regarding the use of Eisai products. Eisai Inc. does not recommend or endorse the use of this product in any manner other than as described in the Full Prescribing Information.

Adverse reactions, some of which can be serious or fatal, may occur with LENVIMA, including hypertension, cardiac dysfunction, arterial thromboembolic events, hepatotoxicity, renal failure or impairment, proteinuria, diarrhea, fistula formation and gastrointestinal perforation, QT interval prolongation, hypocalcemia, reversible posterior leukoencephalopathy syndrome, hemorrhagic events, impairment of thyroid stimulating hormone suppression/thyroid dysfunction, impaired wound healing, osteonecrosis of the jaw, and embryo-fetal toxicity. Click here for Important Safety Information.

LENVIMA indicated:

  • For the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC)
  • In combination with pembrolizumab, for the first line treatment of adult patients with advanced renal cell carcinoma (RCC)
  • In combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy
  • For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)
  • In combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR), as determined by an FDA-approved test, or not microsatellite instability-high (MSI-H), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

Prescribing Information for LENVIMA® (lenvatinib) VIEW/DOWNLOAD

Were the below results helpful?

Thank you for your feedback!

Results showing for ""

 out of

LOAD MORE

Unfortunately, those search terms did not yield results. Please modify search terms or submit a medical inquiry below.

Submit Medical Inquiry 

Would you like to submit a medical inquiry?

Would you like to connect with an MSL?